Skip to main content
Premium Trial:

Request an Annual Quote

BD, Accelr8 Reach Bacterial Dx Development Agreement with License Option

NEW YORK (GenomeWeb News) – Becton Dickinson has solidified an agreement to fund a research program at Accelr8 for rapid bacterial diagnostics, Accelr8 said today.
 
The agreement supports a program running through September 2009, and includes an option that would allow BD to exclusively license Accelr8’s infectious disease diagnostics IP, while Accelr8 would retain the right to commercialize the technology for other applications. If BD exercises that option it will pay an initial fee as well as royalties, and it would be responsible for meeting certain commercialization requirements.
 
BD will fund all product development, manufacturing, and marketing conducted under the license, Accelr8 said.
 
As GenomeWeb Daily News reported in December, Becton Dickinson agreed to pay $100,000 for the right to negotiate with Accelr8 through March 31, 2008, for the new development agreement, and the companies reached an agreement in principle on April 1.